At this exhibition, Guangzhou Baiyunshan Hanfang Modern Pharmaceutical Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group (hereinafter referred to as “Baiyunshan Hanfang”), made its debut with an independent booth at API China. The booth attracted a steady stream of visitors and inquiries.

Building on the dual-exhibition platform, integrating into the Group’s strategy, and expanding the global cooperation network

This joint Shanghai dual-exhibition event represents a crucial opportunity for Baiyunshan Hanfang to leverage the momentum from Guangzhou Pharmaceutical Group’s Suzhou investment promotion conference, deepen its strategic layout in the Yangtze River Delta, and connect with global resources. As a “Little Giant” enterprise recognized by the Ministry of Industry and Information Technology for its specialization, refinement, uniqueness, and innovation, and a benchmark “science-and-technology reform enterprise” certified by the State-owned Assets Supervision and Administration Commission of the State Council, Baiyunshan Hanfang is deeply integrated into Guangzhou Pharmaceutical Group’s “Four Modernizations” strategy—modernization, digitalization, technological advancement, and internationalization—and its “4+4+X” industrial framework. Relying on the Group’s development goal of “Recreating Another Guangzhou Pharmaceutical” during the 15th Five-Year Plan period, Baiyunshan Hanfang adheres to a five-pronged approach—“attracting strategic customers, capital projects, scientific research achievements, high-quality products, and top-tier talent”—to continuously expand its global network of partnerships.

During the exhibition, Chen Jiehui, Deputy Secretary of the Party Committee, Vice Chairman, and General Manager of Guangzhou Pharmaceutical Group, visited Baiyunshan Hanfang’s booth to offer guidance. Yuan Cheng, Party Secretary and Chairman of Baiyunshan Hanfang, provided a detailed report on the company’s product portfolio, breakthroughs in technological innovation, market expansion achievements, and plans for internationalization. Group leaders paid particular attention to the R&D progress, quality control systems, and industrial implementation of Baiyunshan Hanfang’s core products, including its liposome raw material series, fat emulsion excipients, and vinca alkaloid-based anti-cancer APIs.

Previously, Baiyunshan Hanfang had successfully hosted investment promotion conferences alongside Guangzhou Pharmaceutical Group in Wuhan, Haikou, Nanning, Guangzhou, and other cities. Taking advantage of the Shanghai dual-exhibition, Baiyunshan Hanfang has opened its doors to global partners, further strengthening its strategic foothold in the Yangtze River Delta, extending its reach nationwide, connecting globally, and helping the Group build a comprehensive cooperative ecosystem to drive high-quality development in the pharmaceutical industry.

Focusing on core areas, breaking through with cutting-edge products, and showcasing innovative strength in active pharmaceutical ingredients

Baiyunshan Hanfang has been deeply engaged for many years in specialized APIs and high-end injectable lipid excipients, establishing a domestically leading production base for pharmaceutical lipid excipients whose technical standards meet international advanced levels. At this year’s API China exhibition, Baiyunshan Hanfang prominently showcased three major product lines: fat emulsion excipients, key excipients for lipid delivery systems, and anti-cancer APIs. Notably, its liposome raw material series made its public debut, drawing widespread attention.

During the exhibition, Yuan Cheng, Party Secretary and Chairman of Baiyunshan Hanfang, along with Xu Wendong, Deputy Party Secretary and General Manager, led the marketing team in hosting domestic and international partners. They engaged in in-depth discussions on topics such as raw material supply, technological innovation, quality control, and global collaboration, jointly charting a new course for coordinated industrial development.

Meanwhile, Mou Xiaonan, Deputy Director of the Natural Organic Research Lab at Baiyunshan Hanfang’s R&D Center, attended the sub-forum “2026 Pharmaceutical CXO Development Conference,” where she delivered a keynote speech titled “Sharing Quality Attributes and Quality Control Strategies for Complex Injectable Excipients.” Drawing on practical examples from Baiyunshan Hanfang’s lipid excipient quality-control system, she provided an in-depth analysis of key points in the end-to-end quality management of complex injectable excipients, offering valuable solutions for the industry’s pursuit of high-quality development.

Mou Xiaonan, Deputy Director of the Natural Organic Research Lab at Baiyunshan Hanfang’s R&D Center

Looking ahead, anchoring goals and building new heights for the pharmaceutical industry together

Currently, China’s pharmaceutical industry has entered a new phase of high-quality development, with innovation-driven growth, quality enhancement, and international integration emerging as core trends. This Shanghai dual-exhibition marks an important milestone in Baiyunshan Hanfang’s journey—both a concentrated showcase of past innovations and a fresh starting point toward higher-end and more internationalized development.

In the future, Baiyunshan Hanfang will remain committed to its mission of “promoting high-quality development of the pharmaceutical industry and safeguarding public health,” guided by Guangzhou Pharmaceutical Group’s 15th Five-Year Plan strategy. It will continue to play a leading role as a specialized, refined, unique, and innovative “Little Giant” enterprise, focusing on core areas such as pharmaceutical lipid excipients, breaking through critical core technologies, and enhancing product competitiveness and service capabilities. By deepening collaboration across the entire value chain—industry, academia, research, medicine, and finance—and strengthening global supply-chain partnerships, Baiyunshan Hanfang will drive the pharmaceutical industry toward higher-end, smarter, and more internationally oriented development, contributing even greater efforts to the successful implementation of Guangzhou Pharmaceutical Group’s 15th Five-Year Plan and to the overall growth of China’s biopharmaceutical sector.

Yuan Cheng, Party Secretary and Chairman of Baiyunshan Hanfang (sixth from left), Xu Wendong, Deputy Party Secretary and General Manager (fifth from right), posing with the marketing team

#ShanghaiPharmaceuticalExpo #APIExpo #BaiyunshanHanfangAPIs #BaiyunshanHanfang